Advertisement

Topics

Jazz’s Vyxeos Receives FDA Approval for Treatment of Certain Poor Prognosis Acute Myeloid Leukemia

16:05 EDT 3 Aug 2017 | Speciality Pharma Journal

DUBLIN, Aug. 3, 2017 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has approved Vyxeos™ (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Leukemia (AML), a rapidly progressing and life-threatening blood cancer.  Vyxeos is indicated for the …

Original Article: Jazz’s Vyxeos Receives FDA Approval for Treatment of Certain Poor Prognosis Acute Myeloid Leukemia

NEXT ARTICLE

More From BioPortfolio on "Jazz’s Vyxeos Receives FDA Approval for Treatment of Certain Poor Prognosis Acute Myeloid Leukemia"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...